ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

DCE Board Approves Recompetition Concepts

March 18, 1988

In Brief: NIH AIDS William Paul To Step down; Aldige to Lead NCCR; Rimer Joins NCI

October 10, 1997

Recurrent Low-Grade Serous Carcinoma Less Responsive To Chemotherapy

March 28, 2008

Amgen’s Kepivance Approved For Severe Oral Mucositis

January 28, 2005

ASCO Proposes Principles For Future Debate on Medicaid

November 21, 2014

NCI Payline In 1985 Likely To Be 170; $5.9 Million To Be Diverted to AIDS

December 7, 1984